CARsgen's Allogeneic BCMA CAR-T CT0596 Gains NMPA IND Approval for Relapsed/Refractory Multiple Myeloma
核心洞察
CARsgen Therapeutics (搜索) received NMPA investigational new drug (IND) approval for CT0596, its BCMA (搜索)-targeted allogeneic CAR-T therapy for relapsed/refractory multiple myeloma (搜索) (R/R MM).
CT0596 was developed on CARsgen's proprietary THANK-u Plus platform and has shown a favorable safety profile and encouraging efficacy signals in an investigator-initiated trial.
The approval marks a transition from investigator-initiated trials to larger-scale registration clinical trials, potentially accelerating the off-the-shelf CAR-T product's path to market.
CARsgen Therapeutics (搜索) (02171.HK) announced that its self-developed allogeneic CAR-T cell product CT0596 has received investigational new drug (IND) approval from China's National Medical Products Administration (NMPA) for the treatment of patients with relapsed/refractory multiple myeloma (搜索) (R/R MM). The announcement sent the Hong Kong-listed biotech's shares up more than 4% during intraday trading, reaching HK$13.39 with turnover of approximately HK$8.2 million.
CT0596 is a BCMA (搜索)-targeted allogeneic CAR-T cell therapy developed on CARsgen's proprietary THANK-u Plus platform. The product is currently being evaluated in an investigator-initiated trial (IIT) involving patients with R/R MM or plasma cell leukemia (搜索) (PCL), with preliminary results demonstrating a favorable safety profile and encouraging efficacy signals. The IIT results for CT0596 were presented as a poster at the 2026 European Hematology Association (EHA) Annual Meeting, underscoring the academic community's strong interest in the data.
A Next-Generation Approach to Cell Therapy
Unlike most autologous CAR-T therapies currently on the market, which require collecting a patient's own immune cells and undergoing a customized manufacturing process, allogeneic CAR-T (also known as off-the-shelf CAR-T) is widely regarded as a key next-generation direction in cell therapy. The approach offers advantages including mass production potential, greater accessibility, and relatively lower costs — factors that have drawn considerable attention from capital markets.
With this IND approval, CT0596's clinical development in China is expected to formally transition from investigator-initiated trials to larger-scale registration clinical trials, potentially accelerating the product's path to market. Analysts suggest that if allogeneic CAR-T can be successfully commercialized, it could disrupt the existing business model of cell therapy, with significant market potential.
Unmet Need in Multiple Myeloma
From an industry perspective, multiple myeloma (搜索) is one of the most common hematologic malignancies. Although treatment options such as proteasome inhibitors, immunomodulatory drugs, and CD38 antibodies have emerged in recent years, most patients ultimately progress to relapsed or refractory stages, leaving a highly unmet medical need. BCMA (搜索) (B-cell maturation antigen), which is highly expressed on multiple myeloma cells, has become a prominent target for CAR-T therapy.
Expanding Indication Footprint
CARsgen stated that beyond the existing multiple myeloma (搜索) and plasma cell leukemia (搜索) indications, the company plans to further explore CT0596's therapeutic potential in other plasma cell malignancies and autoimmune diseases driven by autoreactive plasma cells, potentially expanding its indication footprint over time.
Remaining Challenges
Some market observers caution that allogeneic CAR-T still faces several technical hurdles in clinical application, including immune rejection of donor-derived cells and insufficient durability. The accumulation and validation of subsequent clinical data will remain key points of focus. Additionally, the competitive landscape is crowded, with numerous global biotech companies actively pursuing this space — whether CARsgen can stand out in the race remains to be seen.
CARsgen Therapeutics (搜索) is a Hong Kong-listed pre-revenue biotech company (B-share) focused on the development of CAR-T cell therapies for solid tumors and hematologic malignancies. The IND approval for CT0596 adds new growth momentum to the company's pipeline, and the market will be closely monitoring its subsequent clinical progress and data readouts.